Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: